Filamentous fungi (moulds) are ubiquitous soil inhabitants whose conidia are inhaled into the respiratory tract, where they may cause life-threatening infections. Among these infections is invasive aspergillosis, which is a major cause of morbidity and mortality in the severely immunocompromised. Risk factors for invasive aspergillosis include 
Introduction
Aspergillus species are ubiquitous soil inhabitants. Alveolar macrophages constitute the first line of host defense against aerosolized conidia. Neutrophils are the dominant host defense against the invasive hyphal stage. Aspergillus infection causes a spectrum of illnesses reflecting the immune status of the host (Figure 1 ). Our review focuses on acute invasive aspergillosis, a major cause of mortality in the highly immunocompromised.
Mortality from invasive aspergillosis has increased several-fold in the 1980s and 1990s [1, 2] , a reflection of more patients undergoing treatment for hematologic malignancies and allogeneic hematopoietic stem cell transplantation (HSCT). Deficits in host defense which render susceptibility to invasive aspergillosis are complex, but can be broadly divided into these categories: 1) neutropenia; 2) qualitative deficits in phagocyte function; and 3) deficits in cellmediated immunity (Table 1 ). We will review the epidemiology, diagnosis, and management of invasive aspergillosis, and strategies for immune augmentation.
Patients at risk for invasive aspergillosis Neutropenia
The risk of invasive aspergillosis is strongly related to the duration and degree of neutropenia. Most cases of neutropenia-associated aspergillosis occur in patients receiving potent cytotoxic regimens for hematologic malignancies and myeloablative HSCT [3] [4] [5] . Invasive aspergillosis is also a major cause of mortality in patients with aplastic anemia and prolonged neutropenia [6] . Multiple cycles of prolonged neutropenia, such as in refractory leukemia, further predispose to invasive filamentous fungal infection. Small foci of invasive fungal disease may be clinically and radiographically inapparent during the initial cycle of neutropenia, but manifest clinically during a subsequent cycle. Concomitant therapy with systemic corticosteroids and other immunosuppressive agents increase the risk of invasive aspergillosis. Therefore, knowledge about current and prior cycles of chemotherapy is key in risk stratification.
Hematopoietic transplantation
Allogeneic HSCT recipients have a higher risk of invasive aspergillosis than autologous HSCT recipients because of the greater intensity of immunosuppression. The spectrum of pathogens to which allogeneic HSCT recipients are most susceptible follows a time line corresponding to the predominant immune defects at different periods (Table 1 ). In the early stage, neutropenia following the conditioning regimen is the principal host defense defect. Most cases of invasive aspergillosis in allogeneic HSCT occur after neutrophil recovery in the setting of potent immunosuppressive therapy for graft-versus-host disease (GVHD) [5, [7] [8] [9] [10] [11] [12] [13] [14] . There are three likely reasons: 1) shortening of the duration of neutropenia period due to infusion of larger numbers of myeloid progenitors and treatment with colony stimulating factors; 2) increased proportion of unrelated donors and HLA-mismatched transplants, which predispose to GVHD; and 3) increased proportion of patients surviving beyond the early transplant period.
Factors associated with an increased risk of invasive aspergillosis in allogeneic HSCT recipients after engraftment include receipt of T cell-depleted or CD34-selected stem cell products, receipt of corticosteroids, neutropenia, lymphopenia, GVHD, and cytomegalovirus disease [12] . Corticosteroids have profound effects on the distribution and function of neutrophils, monocytes, and lymphocytes. Corticosteroids directly stimulate the growth of Aspergillus fumigatus in vitro [16] possibly via sterol binding proteins in the fungus. TNF-is a principal mediator of acute inflammation, and stimulates the activation and recruitment of neutrophils and monocytes. TNF-alpha antagonists used to control GVHD are associated with an increased risk of invasive aspergillosis [17] .
Solid organ transplantation
The period of highest risk for invasive mould infections is generally within the first year of transplant. Intensification of immunosuppressive therapy to treat allograft rejection increases the risk of opportunistic infections. Among SOT recipients, lung transplant recipients are at the highest risk of invasive pulmonary aspergillosis [18] . Anastamotic infections occur in ~5% of lung transplant recipients, and are principally caused by Candida and Aspergillus species [19] .
Infection typically responds to appropriate systemic antifungal therapy, and anastamotic dehiscence is uncommon [19] . Colonization of the native lung with Aspergillus sp., which occurs commonly in end-stage lung disease, is an important source of post-transplant aspergillosis in single lung transplants [20, 21] . Though most cases of post-transplant isolation of an Aspergillus sp. represent transient infection, Cahill et al. [22] reported that only Aspergillus colonization within the first 6 months of transplant was predictive of subsequent invasive disease.
AIDS
Invasive aspergillosis is a relatively uncommon but devastating infection in patients with advanced AIDS [23] [24] [25] [26] [27] [28] . Mortality from opportunistic fungal infections has been reduced with the availability of highly active antiretroviral therapy [1] . A low CD4 count, generally less than 100/ul, was present in almost all cases of AIDS-associated aspergillosis. Co-existent neutropenia or use of corticosteroids occurred in about 50% of patients; the remaining cases appear to have no other risk factors other than advanced AIDS. Isolation of an Aspergillus species from respiratory secretions has poor predictive value for invasive disease in patients with AIDS, and histopathology may be required to establish the diagnosis [29] .
Chronic granulomatous disease
Chronic granulomatous disease (CGD) is an inherited disorder of the NADPH oxidase complexcharacterized by recurrent bacterial and fungal infections. Invasive aspergillosis is the most important cause of mortality in CGD [30] [31] [32] [33] . Despite the routine use of interferonprophylaxis, fungal infections are a persistent problem with an incidence of 0.1 fungal infections per patient year [34] . A randomized, study showed that itraconazole prophylaxis was safe and effective in preventing fungal infections in CGD [36] .
Diagnosis of invasive aspergillosis
Aspergillosis can involve virtually any organ in the immunocompromised host, but sinopulmonary disease is the most common. Angioinvasion of hypae leading to vascular thrombosis and tissue infarction and coagulative necrosis is characteristic of invasive aspergillosis in neutropenia, but is also observed in non-neutropenic allogeneic HSCT recipients with GVHD [Shaukat, 2005 #5002] (Fig. 2) . Early diagnosis of aspergillosis in highly immunocompromised patients remains difficult. Bronchoalveolar (BAL) cultures have approximately 50% sensitivity in focal pulmonary lesions [37] , and definitive diagnosis often requires an invasive procedure (e.g., thoracoscopic biopsy). Isolation of an Aspergillus species from sputum or BAL is highly predicitive of invasive disease in neutropenic patients [38] . A diagnostic algorithm for invasive aspergillosis is summarized in Figure 3 .
Chest CT scans: One or more nodules is the most common finding on chest CT in early invasive pulmonary aspergillosis in neutropenic patients and HSCT recipients, and may be inapparent on The value of surveillance serum galactomannan monitoring is unclear. In the best scenario, prospective serial monitoring of galactomannan antigenemia in allogeneic HSCT recipients yielded positive and negative predictive values of 94.4% and 98.8%, respectively, and antigenemia preceded radiographic findings by more than a week in 80% of cases of invasive aspergillosis [48] . In another study, the sensitivity was only 64.5% in cases of definite invasive aspergillosis [49] . The positive predictive value (PPV) was poor when used as a surveillance tool in patients with persistent neutropenic fever (PPV=7.1%) and in HSCT (mostly autologous) recipients (PPV=10%). In a study of 170 patients at high risk for invasive mould infection from North American cancer centers, the galactomannan assay identified 25 of 31 patients with invasive aspergillosis (81% sensitivity), and had a specificity of 89%
(http://www.fda.gov/bbs/topics/NEWS/2003/NEW00907.html). The lack of consistent results likely relate to different cut-off values for a positive result, differences in patient populations, and possibly practices involving use of mould-active prophylaxis. Further studies will be required to demonstrate whether surveillance galactomannan testing in targeted high-risk patients will translate into improved outcomes.
Detection of serum B-glucan, a fungal cell wall constituent, has recently received FDA approval. Inpatients with acute myeloid leukemia and myelodysplastic syndrome, the assay was highly sensitive and specific in detecting early invasive fungal infections, including candidiasis, fusariosis, trichosporonosis, and aspergillosis [50] . The value of the B-glucan assay in other patient groups at high risk for invasive fungal infections is unknown.
PCR-based detection of aspergillosis applied to blood [51] [52] [53] and BAL [54] [55] [56] is another promising tool for early diagnosis. Specific primers and conditions vary in published series, and will require standardization and validation in reference laboratories before they can be widely applied. Prospective studies are required to define which diagnostic methods -or combination of methods -confer optimal sensitivity and specificity in detecting early Aspergillus infection.
Therapy for invasive aspergillosis
There have been important new developments in antifungal agents (Table 2) .
Voriconazole was more effective than amphotericin B as initial therapy for invasive aspergillosis and was associated with significantly improved survival (71% vs. 58%, respectively) [57] . The rate of successful outcomes was superior in voriconazole compared to amphotericin B recipients (53% versus 32% respectively). The poorest prognosis occurred in extrapulmonary aspergillosis and in allogeneic HSCT recipients. Voriconazole led to a successful outcome in 34% of patients with central nervous system aspergillosis [58] , an infection previously associated with almost universal mortality [25] . Voriconazole appears to have comparable safety and efficacy in children with invasive mould infections compared to adults [59] . Aspergillus terreus has been observed with increased frequency at several cancer centers, and is notable for being resistant to amphotericin B, but sensitive to voriconazole [60, 61] . We advise voriconazole as first-line therapy for invasive aspergillosis. an azole or an amphotericin B formulation occurred in some animal models of aspergillosis [62] [63] [64] but not in others [65] [66] [67] .
The combination of caspofungin and liposomal amphotericin B as salvage therapy led to a favorable outcome in approximately 40% to 60% of patients with invasive aspergillosis, though these series included cases of "possible" aspergillosis [68, 69] . Marr et al. [70] reported a survival advantage of voriconazole plus caspofungin compared to voriconazole alone in a retrospective analysis of salvage therapy for invasive aspergillosis. This database involved small numbers of patients and the two groups were non-contemporaneous; therefore, other host and infection-related factors may have influenced the outcome. A randomized, prospective study is required to definitively assess the benefit of combination antifungal therapy in invasive aspergillosis.
Posaconazole, an experimental azole, has been effective as salvage therapy against a broad spectrum of invasive fungal infections [71] . Forty-one percent of patients with invasive aspergillosis that was refractory or who had intolerance to standard antifungal therapy had a complete or partial response to posaconazole [71] . In a pilot study of CGD patients with invasive mould infections refractory to voriconazole, posaconazole was safe and effective [72] .
Patients who recover from an episode of invasive aspergillosis are at risk for recurrence during subsequent immunosuppression [73, 74] . In patients with invasive aspergillosis prior to HSCT, antifungal therapy for more than a month and resolution of radiologic abnormalities correlate with a lower likelihood of post-transplant recurrence of infection [74] .
Secondary prophylaxis with a mould active agent is advised for the entire period of immunosuppression.
Debridement of locally invasive disease, such as sinusitis or primary cutaneous aspergillosis should be performed when feasible. Resection of localized pulmonary aspergillosis prior to undergoing subsequent allogeneic HSCT has been advised based on small numbers of patients [10] . With more effective and safer antifungal agents that enable administration of prolonged therapy, the value of "pre-emptive" resection in cases of pulmonary aspergillosis responding to antifungal therapy is unclear.
Immune augmentation strategies Augmentation of neutrophil number
Colony Stimulating Factors: Colony stimulating factors (CSF) are used to accelerate myelopoiesis in neutropenic patients. Prophylaxis with a CSF can reduce the incidence of neutropenic fever by as much as 50%, which in some studies translated into a reduction in hospitalization and use of antibiotics [75] . In one randomized study in patients receiving chemotherapy for acute myelogenous leukemia, prophylaxis with granulocyte-macrophage colony-stimulating factor (GM-CSF) led to a lower frequency of fatal fungal infections compared to placebo (1.9% versus 19%, respectively) and reduced overall early mortality [76, 77] .
However, CSFs have not produced a survival advantage in the remainder of studies.
CSFs also augment phagocyte function. Granulocyte colony-stimulating factor (G-CSF), promise as adjunctive therapeutics for invasive fungal infections. We will focus on rIFN-g because the database is the most developed [90] . IFN-augments innate and Th1-dependent immunity, both of which contribute to host defense against Aspergillus infection. IFNaugmented human neutrophil oxidative response and killing of Aspergillus hyphae in vitro, and acted additively with G-CSF [78] . It prevented corticosteroid-mediated suppression of neutrophil killing of hyphae [91] , and enhanced killing of Aspergillus hyphae by human monocytes [79] .
Administration of rIFN-to CGD patients augmented ex-vivo neutrophil-mediated damage of Aspergillus hyphae, presumably through non-NADPH oxidase dependent pathways [92] . In animal models, augmentation of the Th1/Th2 cytokine balance either through administration or depletion of cytokines conferred protection in experimental aspergillosis [93] [94] [95] [96] [97] .
rIFN-is licensed as a prophylactic agent in patients with CGD based on a randomized trial in which IFN-reduced the number and severity of infections (mostly bacterial) in CGD by about 70%, [98] . Data on rIFN-as adjunctive therapy for invasive aspergillosis are limited to case reports and small series [99, 100] , and no recommendation about its use in this setting can be made. It was disappointing that a randomized trial evaluating rIFN-as adjunctive therapy for invasive aspergillosis was prematurely terminated before any patient was enrolled. One concern about rIFN-in allogeneic HSCT recipients is the potential for worsening GVHD. Though preliminary results suggest that rIFN-g is safe in allogeneic HSCT recipients [99, 100] , the safety of rIFN-can not be predicted based on this limited database, and therefore merits evaluation in a clinical trial with safety as the primary endpoint.
Innate Pathogen Recognition Pathways
Toll like receptors: Toll-like receptors (TLR) recognize common pattern motifs on microbes, and initiate T-cell and DC maturation. Aspergillus conidia, but not hyphae, stimulate macrophages to produce the proinflammatory cytokines TNF-alpha and IL-1 in a TLR4-dependent fashion [101] . In contrast, Aspergillus hyphae, but not conidia, stimulated production of the anti-inflammatory cytokine IL-10 through TLR2-dependent mechanisms. This switch from a proinflammatory to anti-inflammatory signals during germination may help Aspergillus evade host defense. Others found that both TLR 2 and 4 recognize Aspergillus hyphae, stimulate proinflammatory cytokines in effector cells, and stimulate neutrophil recruitment [102, 103] .
Local delivery of CpG oligodeoxynucleotides (which signal through TLR 9) and the Aspf16 Aspergillus allergen resulted in activation of airway DCs capable of inducing Th1 priming and resistance to the fungus in mice [104] . Thymosin alpha 1, a naturally occurring thymic peptide, induced maturation and IL-12 production in DCs pulsed with Aspergillus, an effect mediated by distinct TLRs [105] . Thymosin alpha 1 augmented Th1 immunity against Aspergillus, accelerated myeloid recovery in neutropenic mice, and was protective against
Aspergillus challenge in murine HSCT recipients.
Recognition of Aspergillus motifs and activation of neutrophils is coordinated by distinct members of the TLR family, each likely activating specialized antifungal effector functions and inflammatory responses [106] . Indeed, liposomal amphotericin B, in addition to its intrinsic antifungal activity, may activate antifungal resistance by activating TLR-4 in neutrophils [107] .
These studies provide a rationale to stimulate or inhibit specific classes of TLRs to enhance innate and antigen-specific immunity to fungi (Table 3) .
Pentraxins: Pentraxin (PTX) 3 is an innate pathogen recognition protein that binds to specific motifs on A. fumigatus and other pathogens. PTX3-deficient mice had defective recognition of conidia by alveolar macrophages and DCs, inappropriate induction of type 2 cytokine responses, and were highly susceptible to Aspergillus infection [108] . Administration of PTX3 protected against Aspergillus challenge in murine HSCT recipients [108] , and potentiated the protective effect of sub-therapeutic amphotericin B [109] .
Vaccines
Vaccine development is a priority for several fungal pathogens and requires knowledge about host-pathogen interactions [110, 111] .
The importance of cell-mediated immunity against
Aspergillus infection has become well established in mice [93] [94] [95] [96] . Immunization of immunocompetent mice with an Aspergillus crude filtrate resulted in memory responses mediated by antigen-specific, Th-1-committed CD4+ T-cells [112] . Adoptive transfer of these cells conferred protection to neutropenic mice --establishing a "proof of principle" regarding the cellular immunity as a target for immune augmentation in invasive aspergillosis [112] . protection against aspergillosis [113] . DCs are also key in containing and dampening inflammatory responses by tolerization through the induction of regulatory T cells (Treg) [114] .
These studies in mice demonstrate the functional plasticity of DCs in response to fungi that can be exploited in vaccine development [114] [115] [116] .
Genomics
Fungal genomics offers an opportunity to develop novel antifungal agents that is complementary to traditional drug screening methods focused on existing targets. DNA microarray chips for A. fumigatus are now being made available to investigators through The
Institute for Genomic Research (TIGR).
Genomics will be an important tool in understanding the molecular biology of Aspergillus and will facilitate the identification of novel virulence genes. Emerging experimental analysis tools, such as chemogenomics, fitness profiling, transcript profiling and proteomics will further enhance the analysis of genome-wide functional studies [117] . This knowledge may be exploited to identify novel targets for drug discovery. Moreover, characterizing gene profiles of host cells In allogeneic HSCT recipients, the risk of opportunistic fungal infections is reduced at 6 months or more after transplanation in the absence of GVHD. However, GVHD requiring intensive immunosuppressive therapy (e.g., corticosteroids) disables neutrophil and macrophage function as well as reconstitution of cellular and humoral immunity. Such patients are at high risk for late transplant invasive fungal infections. Other risk factors for invasive mould infections in allogeneic HSCT recipients after neutrophil recovery include: human leukocyte antigen haplotype-mismatched or unrelated donors, T-cell depleted allografts, lymphopenia, cytomegalovirus disease, and receipt of multiple stem cell transplants. 
